Pfizer: Why Being Bullish Makes Sense Despite The Patent Cliff (NYSE:PFE)
· seekingalpha.com
Pfizer continues to focus on its portfolio of drugs. Read how the company may navigate the patent cliff. Click here to read more on PFE.
When Pfizer ( PFE ) was coming out of the COVID-induced growth phase in early 2024, I turned bullish alongside CEO Albert Bourla, who effectively is betting his...